“Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s279. https://doi.org/10.25251/skin.7.supp.279.